Patent ID: 11944674
Assignee: OXFORD UNIVERSITY INNOVATION LIMITED
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  Y | IPC A

Claim 5:
6. The fusion polypeptide or particle as claimed in claim 1, wherein the amino acid sequence derived from the C-terminal fragment of CSP of P. vivax is:
(a) an amino acid sequence having at least 80% sequence identity to one or more of SEQ ID NOs: 29-32 and comprising one or more T-cell epitopes which promote the immunogenicity of the Type I and/or Type II repeat units; or
(b) a fragment of SEQ ID NOs: 29-32 which is at least 50% of the length of SEQ ID NOs: 29-32 and comprises one or more T-cell epitopes which promote the immunogenicity of the Type I and/or Type II repeat units,
and/or, wherein the amino acid sequence derived from the Hepatitis B virus surface antigen is:
(a) an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 38 and having the ability to increase the immunogenicity of parts (i)-(iii) of the fusion polypeptide of claim 1; or
(b) a fragment of SEQ ID NO: 38 which is at least 80% of the length of SEQ ID NO: 38 and having the ability to increase the immunogenicity of parts (i)-(iii) of the fusion polypeptide of claim 1.